Akira Morimoto

Akira Morimoto

Auto-generated profile, based on publicly available information

Akira Morimoto

Division of Pediatrics, Showa Inan General Hospital, Komagane, Japan

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2014 in Pediatrics International
Verified
Journal Article
Open access
PDF file
AMAkira Morimoto
Akira Morimoto
YOYukiko Oh
Yukiko Oh
YSYoko Shioda
Yoko Shioda
KKKazuko Kudo
Kazuko Kudo
TIToshihiko Imamura
Toshihiko Imamura
The purpose of this review is to provide an updated overview of the pathogenesis and treatment of Langerhans cell histiocytosis (LCH). The pathogenesis of LCH remains obscure and the optimal treatment for LCH has not been established, although incremental progress has been made. Proinflammatory cytokines and chemokines are known to play a role in LCH, which suggests that LCH is an immune disorder. However, the oncogenic BRAF mutation is also detected in more than half of LCH patients, which suggests that LCH is a neoplastic disorder. Remaining major issues in the treatment of LCH are how to rescue patients who have risk‐organ involvement but do not respond to first‐line therapy, the optimal treatment for the orphan disease of multifocal adult LCH, and how to reduce and treat central nervous system‐related consequences, such as central diabetes insipidus and neurodegeneration. More research is needed to better understand the pathogenesis of this disease and to resolve the treatment issues.

4 April 2016 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
AMAkira Morimoto
Akira Morimoto
YSYoko Shioda
Yoko Shioda
TIToshihiko Imamura
Toshihiko Imamura
KKKazuko Kudo
Kazuko Kudo
HKHiroshi Kawaguchi
Hiroshi Kawaguchi
SIShinsaku Imashuku
Shinsaku Imashuku

22 February 2015 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
IMIchiro Murakami
Ichiro Murakami
MMMichiko Matsushita
Michiko Matsushita
TITakeshi Iwasaki
Takeshi Iwasaki
SKSatoshi Kuwamoto
Satoshi Kuwamoto
MKMasako Kato
Masako Kato
Tadashi YoshinoTadashi Yoshino
Tadashi Yoshino
We propose Langerhans cell histiocytosis (LCH) is an inflammatory process that is prolonged by mutations. We hypothesize that Merkel cell polyomavirus (MCPyV) infection triggers an interleukin-1 (IL-1) activation loop that underlies the pathogenesis of LCH. Langerhans cells (LCs) are antigen presenting cells in the skin. When LCs encounter exogenous antigens, they migrate from the epidermis into draining lymphoid tissues to initiate T-cell activity. It has been proposed that LC migration-related factors, including E-cadherin, matrix metalloproteinase, and Notch ligand induce LCH activity. We found that the tyrosine phosphatase SHP-1, which binds IL-1 receptor-associated kinase 1, is expressed at a significantly higher level in LCH affecting multiple organ systems (MS-LCH) than in LCH affecting a single organ system (SS-LCH). IL-1 stimulates T helper 17 cells and their signature cytokine IL-17 had been a matter of controversy. We detected higher levels of IL-17A receptor expression in MS-LCH than in SS-LCH and proposed an IL-17 endocrine model that could settle the controversy. IL-1 is the first cytokine secreted in response to sensitizers and promotes LC migration from sentinel tissues. Myeloid differentiation primary response 88 (MyD88), downstream of the IL-1 receptor, has functions in both RAS signaling and inflammation, leading to human cell transformation. In 2010, an activating mutation in the B-rapidly accelerated fibrosarcoma gene (BRAF) V600E was found in LCH. This BRAF mutation induces phosphorylation of the extracellular signal-regulated kinase (ERK) that may play an important role with MyD88 in LCH pathogenesis. However, phosphorylated ERK (pERK) is rapidly dephosphorylated by dual specificity phosphatase 6 (DUSP6), and limited proliferation is predicted in BRAF mutant cells. MyD88 binds pERK via its D-domain, thereby preventing pERK–DUSP6 interaction and maintaining ERK in an active, phosphorylated state. We detected MCPyV-DNA in the peripheral blood cells of two out of three patients with LCH in high-risk organs but not in those of patients with LCH in non–high-risk organs (0/12; P = .029). MCPyV infection can trigger precursor LCH cells with BRAF mutation to produce IL-1; the IL-1 loop is amplified in all LCH subclasses. Our model indicates both BRAF mutation and IL-1 loop regulation as potential therapeutic targets.

2 September 2009 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
AMAkira Morimoto
Akira Morimoto
YIYasushi Ishida
Yasushi Ishida
NSNobuhiro Suzuki
Nobuhiro Suzuki
SOShouichi Ohga
Shouichi Ohga
YSYoko Shioda
Yoko Shioda
HHHLH/LCH Committee of the Japanese Society of Pediatric Hematology
HLH/LCH Committee of the Japanese Society of Pediatric Hematology

1 September 2017 in Cytokine
Verified
Journal Article
Closed access
AMAkira Morimoto
Akira Morimoto
YOYukiko Oh
Yukiko Oh
SNSachie Nakamura
Sachie Nakamura
YSYoko Shioda
Yoko Shioda
THTomomi Hayase
Tomomi Hayase
SIShinsaku Imashuku
Shinsaku Imashuku

10 December 2014 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
J(Japan LCH Study Group (JLSG)
Japan LCH Study Group (JLSG)
Shinsaku ImashukuShinsaku Imashuku
Shinsaku Imashuku
NFNaoto Fujita
Naoto Fujita
YSYoko Shioda
Yoko Shioda
HNHaruyoshi Noma
Haruyoshi Noma
AMAkira Morimoto
Akira Morimoto